IBEC has signed a collaboration agreement with Bioibérica S.A., a company specialised in the R&D, production and sale of biomolecules and new technologies for the pharmaceutical, veterinary and agrochemical industries. It’s the latest success story in IBEC’s active pursuit of the establishment of research projects with industry partners who share its commitment to bringing high-quality health research and technologies to market and the patient.
Together, IBEC – specifically its Nanomalaria joint unit with ISGlobal, led by Xavier Fernández-Busquets – and Bioibérica, which since its formation in 1975 has focused on the investigation and production of biomolecules extracted from animal tissue with significant biological and therapeutic properties, will explore ways of combining their expertise to achieve advances in future medicine.
For more information about the company, visit their website here.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The results show that adenocarcinoma exhibits much more active and fun...
